Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AEON Biopharma, Inc. (AEON : AMEX)

• Company Description    AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.10 Daily Weekly Monthly 20 Day Moving Average: 187,314 shares Shares Outstanding: 11.84 (millions) Market Capitalization: $13.02 (millions) Beta: 0.72 52 Week High: $1.41 52 Week Low: $0.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 46.96% 47.21% 12 Week 6.80% 5.07% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5 PARK PLAZA SUITE 1750 - IRVINE,CA 92614 USA ph: 949-354-6499 fax: - laurence@newstreetir.com http://www.aeonbiopharma.com

• General Corporate Information    Officers Marc Forth - President; Chief Executive Officer and Director Jost Fischer - Chairman Jennifer Sy - Vice President; Corporate Controller Shelley Thunen - Director Robert Palmisano - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00791X209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 11.84 Most Recent Split Date: 2.00 (0.01:1) Beta: 0.72 Market Capitalization: $13.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 0.41 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 96.61% vs. Previous Quarter: 35.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -101.30 06/30/25 - -136.03 Current Ratio 12/31/25 - - 09/30/25 - 0.90 06/30/25 - 1.12 Quick Ratio 12/31/25 - - 09/30/25 - 0.90 06/30/25 - 1.12 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - -1.71 06/30/25 - -1.37 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©